<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(4)</volume><submitter>Chu W</submitter><funding>National Natural Science Foundation of China</funding><journal>Clinical and translational medicine</journal><pagination>e791</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8982313</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.</pubmed_title><pmcid>PMC8982313</pmcid><funding_grant_id>81872785</funding_grant_id><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Chu W</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Xie Z</pubmed_authors><pubmed_authors>Wang G</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Geng M</pubmed_authors><pubmed_authors>Tan X</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Xia N</pubmed_authors><pubmed_authors>Luo W</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Chen YL</pubmed_authors></additional><is_claimable>false</is_claimable><name>HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.</name><description/><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-04T22:17:10.467Z</modification><creation>2025-04-04T22:17:10.467Z</creation></dates><accession>S-EPMC8982313</accession><cross_references><pubmed>35384333</pubmed><doi>10.1002/ctm2.791</doi></cross_references></HashMap>